Cerezyme
Links shared publicly online about this topic
FDA Alert: Genzyme Products, Marketed as Cerezyme, Fabrayzme, Myozyme, Aldurazyme, and Thyrogen
drugs.com — “FDA Alert: Genzyme Products, Marketed as Cerezyme, Fabrayzme, Myozyme, Aldurazyme, and Thyrogen” View full resource at drugs.com
Most Recently Shared on November 14, 2009 at 3:51 am By:
FDA Alert - FDA Warns of Potential for Foreign Particle Contamination in Several Genzyme Products - http://bit.ly/4puEJt
Genzyme Producing More Cerezyme for Gaucher's Disease - Health Blog - WSJ
blogs.wsj.com — “New lots of the company's treatment for Gaucher's disease won't be available until November.” View full resource at blogs.wsj.com
Most Recently Shared on August 11, 2009 at 4:54 pm By:
Genzyme Resumes Production, But Patients Still Waiting http://bit.ly/l3qgj
Genzyme set for Cerezyme supply boost - FiercePharma
fiercepharma.com — “It's good news and bad news for Genzyme. The good news is that the company has written patients to say it will boost shipments of its Gaucher disease drug Cerezyme next month, just as it promised... Read more...” View full resource at fiercepharma.com
Most Recently Shared on August 27, 2010 at 1:19 pm By:
Genzyme set for Cerezyme supply boost. http://bit.ly/cnqs5M
2d Cerezyme rival available in trials - The Boston Globe
boston.com — “For the second time in two weeks, federal regulators have moved to counter the ongoing supply shortage of Cerezyme, Genzyme Corp.’s treatment for Gaucher disease, by letting doctors prescribe a rival drug before it has won approval for commercial use.” View full resource at boston.com
Most Recently Shared on August 18, 2009 at 1:34 pm By:
Twice in 2 weeks, FDA allows docs to prescribe unapproved Gaucher's drug to make up for shortage of market-leading drug http://tr.im/wBJE
Information for Healthcare Professionals - Potential Contamination of Products Manufactured by Genzyme Corporation, Marketed as Cerezyme, Fabrayzme, Myozyme, Aldurazyme, and Thyrogen
fda.gov — “Fda is warning healthcare professionals about the potential for foreign particle contamination of several products manufactured by genzyme corporation that are used to treat rare, serious, and life-threatening diseases.” View full resource at fda.gov
Most Recently Shared on November 13, 2009 at 4:49 pm By:
Chris Morrison Health Communicator
Not good. Genzyme gets tagged by FDA again. this time--particle contamination in some lots of several products http://bit.ly/2W9Oia
WRAPUP 1-Genzyme, rivals battle for place in Gaucher market | Reuters
reuters.com — “* Rivals present data at conference in Miami * Drugs appear to show similar efficacy * Genzyme hopes to keep grip on market with oral drug By Toni Clarke BOSTON, Feb 11 (Reuters) - Shire Plc ” View full resource at reuters.com
Most Recently Shared on February 12, 2010 at 12:28 pm By:
John Carroll Health Communicator
Oppenheimer: "...Shire and Protalix will erode about one-third of Genzyme's Cerezyme market share over time." http://bit.ly/a2XQCP
Hospira helps Genzyme tackle manufacturing problems | InPharm
inpharm.com — “Hospira helps Genzyme tackle manufacturing problems | InPharm” View full resource at inpharm.com
Most Recently Shared on January 6, 2010 at 9:45 am By:
Pharmafocus Health News and Pharma
Hospira helps Genzyme tackle manufacturing problems. Will work on products including Cerezyme and Fabrazyme. http://ow.ly/TcUg
Genzyme discloses contamination at Ireland plant - Boston Business Journal
boston.bizjournals.com — “Genzyme discloses contamination at Ireland plant - Boston Business Journal” View full resource at boston.bizjournals.com
Most Recently Shared on March 12, 2010 at 10:41 pm By:
Lisa Jarvis Science Enthusiast
Genzyme's manufacturing woes mount: it notifies customers of impure vial of Cerezyme at Ireland plant: http://bit.ly/cHXXXw $GENZ
Genzyme Reports Financial Results for the First Quarter of 2010
businesswire.com — “CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that first-quarter revenue was $1.07 billion, compared with $1.15 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints. GAAP net loss was $114.9 million, or $0.43 per diluted share, compared with net income of $195.5 million, or $0.70 per diluted share, in the first quarter of 2009. GAAP r” View full resource at businesswire.com
Most Recently Shared on April 21, 2010 at 1:47 pm By:
Genzyme Reports Financial Results for the First Quarter of 2010: http://bit.ly/cUv1el
wbur.org » News » Cambridge Pharmaceutical Company Fined $175M
wbur.org — “Genzyme has to pay the fine for contamination problems at its Allston manufacturing plant. Those problems led to the shortages of two drugs, Fabrazyme and Cerezyme.” View full resource at wbur.org
Most Recently Shared on April 21, 2010 at 6:09 pm By:
Cambridge Pharmaceutical Company Fined $175M: Genzyme has to pay the fine for contamination problems at its All.. http://bit.ly/dqI3MY
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year | Business Wire
businesswire.com — “Genzyme Corp. (NASDAQ: GENZ) today reported fourth-quarter 2010 results that reflect increasing supplies of Cerezyme® (imiglucerase for injection)” View full resource at businesswire.com
Most Recently Shared on February 16, 2011 at 1:30 pm By:
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year http://bit.ly/eaHU23
FDA warns of particulate contamination of Genzyme injectable products - MPR
empr.com — “The FDA and Genzyme have notified healthcare professionals about the potential for foreign particle contamination of certain lots of Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alpha), Aldurazyme (laronidase), and Thyrogen (thyrotropin alpha).” View full resource at empr.com
Most Recently Shared on November 13, 2009 at 8:09 pm By:
MPR News: FDA warns of particulate contamination of Genzyme injectable products: The FDA and Genzyme have notified ... http://bit.ly/1Vdhgj
News Blog: Virus hits Genzyme plant, halting production of orphan drugs
scientificamerican.com — “Over the weekend, drugmaker Genzyme shut down a Massachusetts factory after a virus infected hamster ovary cells used to produce Fabrazyme and Cerezyme, drugs for two rare genetic disorders . Genzyme is the sole supplier of the medicines in” View full resource at scientificamerican.com
Most Recently Shared on June 17, 2009 at 8:42 pm By:
Scientific American Health Magazine
Virus hits Genzyme plant, halting production of orphan drugs: Over the weekend, drugmaker Genzyme shut down a Ma.. http://tinyurl.com/mgek7r
Genzyme touts 2-year results for oral Gaucher drug - FierceBiotech
fiercebiotech.com — “Genzyme touted the two-year results for its mid-stage study of a new oral pill for Gaucher disease, saying it looks comparable to its blockbuster Cerezyme. Investigators say that eliglustat tartrate Read more...” View full resource at fiercebiotech.com
Most Recently Shared on February 11, 2010 at 4:37 pm By:
Genzyme touts 2-year results for oral Gaucher drug. http://is.gd/8anzX
Genzyme Reports Financial Results for the Second Quarter of 2010
businesswire.com — “CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year. GAAP net income was $23,000, or $0.00 per dilu” View full resource at businesswire.com
Most Recently Shared on July 21, 2010 at 2:08 pm By:
Genzyme Reports Financial Results for the Second Quarter of 2010 http://bit.ly/9lVns7
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
WSJ Health Blog
The WSJ Health Blog offers insight and analysis on health and health biz.
-
FiercePharma
FiercePharma's 140. Join 50,000 pharma insiders on our free newsletter at FiercePharma.com
Advertisement
